Clinical trials: Oral Anticoagulant
Venous Thromboembolism, Deep Vein Thrombosis
RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
Lower limb trauma requiring immobilization is a very frequent condition that is associated with an increased risk of developing venous thromboembolism (VTE).
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism, Lower Limb Trauma
- Trial name
- RIVACAST (NCT06195540)
- Testing
- Rivaroxaban 10 MG, Low Heparin Molecular Weight
- Where
- 37 sites in France
- Volunteers
- 1,424 people
- Sponsor
- University Hospital, Angers
Venous Thromboembolic Disease
Cost Effectiveness Analysis of an Ancillary Study of the REMOTEV Study
The implications of the medico-economic impact are essential in the choice of first-line therapists. The economic impact is an important criterion to recommend the privileged use of Direct Oral Anticoagulants (AOD) in first…
- Trial name
- NCT03887806
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Prevention of Thromboembolic Events, Atrial Fibrillation
An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting
This is an observational study in which data from people with atrial fibrillation who received or are currently receiving the drug apixaban to prevent thromboembolic events (blood clots that travel through the blood stream to…
- Trial name
- NCT05471830
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bayer
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
Liver Cirrhosis
Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
The aim of this study is to investigate the pharmacokinetic and pharmacodynamic parameters of rivaroxaban and apixaban in patients with compensated liver cirrhosis (Child-Pugh class A and B).
- Trial name
- NCT04874428
- Testing
- Rivaroxaban 10 mg Oral Tablet, Apixaban 2.5 mg Oral Tablet
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Anticoagulant-induced Bleeding
DOAC Versus VKA After Cardiac Surgery
Postoperative management of oral anticoagulation is a frequent preoccupation in cardiac surgery, concerning about half of patients.
- Trial name
- DOAC/VKA (NCT04002011)
- Testing
- Warfarin, Dabigatran, Rivaroxaban
- Sponsor
- Laval University
Gastrointestinal Bleeding
Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants
Gastrointestinal bleeding (GIB) is a common emergency in hepatology and gastroenterology, with an overall mortality rate ranging from 5% to 10% depending on the study.
- Trial name
- HEMOD-AOD (NCT07333144)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Strasbourg, France
Hemorrhage, Surgical, Hemorrhage Postoperative
Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)
Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery
- Conditions
- Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
- Trial name
- STAR-D (NCT05093504)
- Testing
- DrugSorb-ATR system
- Where
- 27 sites in United States
- Volunteers
- 9 people
- Sponsor
- CytoSorbents, Inc
LVAD (Left Ventricular Assist Device) Thrombosis
DOT HeartMate 3 Study
A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.
- Trial name
- NCT04974684
- Testing
- HeartMate 3, Apixaban
- Where
- Czechia
- Volunteers
- 45 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Atrial Fibrillation
This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain
The primary objective of the study is to describe the usage of NOACs in patients with NVAF, in the hospital setting, based on the baseline characteristics at the time of first NOAC initiation.
- Trial name
- RE-CONOCE (NCT03285373)
- Testing
- NOAC
- Where
- 75 sites in Spain
- Volunteers
- 1,008 people
- Sponsor
- Boehringer Ingelheim
Endstage Renal Disease, Direct Oral Anticoagulants (DOACs)
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1].
- Conditions
- Endstage Renal Disease, Direct Oral Anticoagulants (DOACs), Arteriovenous Fistula, Arteriovenous Fistula Occlusion
- Trial name
- NCT07559942
- Testing
- Apixaban
- Where
- Pakistan
- Volunteers
- 190 people
- Sponsor
- Combined military hospital lahore
Anticoagulant, Perioperative
Direct Oral Anticoagulant Management for Cardiac Device Implantation
Each year, tens of thousands of cardiac rhythm devices including pacemaker (PM) or implantable cardioverter-defibrillator (ICD) are implanted in France.
- Trial name
- StimAOD (NCT03879473)
- Where
- France
- Volunteers
- 680 people
- Sponsor
- Institut Necker Enfants Malades
Atrial Fibrillation
AIHEMAF - P "An Innovative Healthcare Model for AF Patients"
Non-profit observational study on the role of the community pharmacist and "the pharmacy of services" in the case management of patients suffering from atrial fibrillation and being treated with new generation oral anticoagulants
- Trial name
- AIHEMAF - P (NCT05086991)
- Testing
- Follow up
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Farmacia La Regina s.r.l.
Coagulation Disorder
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
A single centre, double-blind, randomized, parallel group, placebo-controlled study in healthy subjects conducted in two parts: Part 1: Single ascending doses in healthy subjects aged 18 to 49 years to assess safety…
- Trial name
- NCT05152420
- Testing
- VMX-C001, Apixaban, Rivaroxaban
- Where
- Netherlands
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Atrial Fibrillation
Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation
To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period.
- Trial name
- NCT03187197
- Testing
- Pradaxa®
- Where
- 24 sites in Taiwan
- Volunteers
- 1,315 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)
The purpose of this observational study is to identify participants with both minor and major bleeds as a result of anticoagulant treatment for AF and evaluating their QoL through both primary and secondary care settings.
- Trial name
- EQUAL-AF (NCT05044533)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Bristol-Myers Squibb
Renal Insufficiency
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic…
- Trial name
- VERDICT (NCT02664155)
- Testing
- Apixaban, Rivaroxaban, Heparin
- Where
- 31 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Surgery
Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.
- Trial name
- Annexa-S (NCT04233073)
- Testing
- andexanet alfa
- Where
- 56 sites in United States, Austria and 4 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Oral Antiplatele, Anticoagulant Drugs
Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation
This observational study aims to assess the effect of oral antiplatelet or anticoagulant drugs on key postoperative outcomes in patients with lower extremity varicose veins who have undergone radiofrequency ablation.
- Conditions
- Oral Antiplatele, Anticoagulant Drugs, Lower Extremity Varicose Veins, Radiofrequency Ablation
- Trial name
- NCT07208695
- Testing
- Antiplatelet or Anticoagulant Drugs
- Volunteers
- 40 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Atrial High Rate Episodes
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
NOAH is an investigator-initiated, prospective, parallel-group, double-blind, randomised, multi-centre trial. The objective of the trial is to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current…
- Trial name
- NOAH (NCT02618577)
- Testing
- Edoxaban, ASA
- Where
- 18 sites in Austria, Belgium and 16 more
- Volunteers
- 2,608 people
- Sponsor
- Atrial Fibrillation Network